Latest Healthcare News

Page 11 of 182
AVITA Medical reported a mixed fourth quarter with revenue pressures easing and full-year growth, underpinned by a new $60 million credit facility and advancing clinical trials.
Ada Torres
Ada Torres
13 Feb 2026
AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.
Ada Torres
Ada Torres
13 Feb 2026
AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.
Ada Torres
Ada Torres
13 Feb 2026
AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.
Ada Torres
Ada Torres
13 Feb 2026
Osteopore Limited has secured an exclusive three-year distribution deal with Medprin Biotech GmbH to broaden its presence in Latin America's craniofacial reconstruction market, tapping into a region poised for significant growth.
Ada Torres
Ada Torres
13 Feb 2026
Ramsay Health Care has cleared a major regulatory hurdle with ACCC approval to acquire National Capital Private Hospital, setting the stage for completion in early fiscal 2027.
Ada Torres
Ada Torres
13 Feb 2026
Cochlear Limited reported a modest 1% rise in HY26 sales revenue to $1.176 billion, but underlying net profit fell 9% amid slower-than-expected contract renewals for its new Nucleus Nexa implant system. The company anticipates a stronger second half and maintains full-year guidance at the lower end of its forecast.
Ada Torres
Ada Torres
13 Feb 2026
Cochlear Limited reported a modest 1% rise in sales but a 9% fall in underlying net profit for the half year ended December 2025, as the rollout of its innovative Nucleus Nexa System faced longer-than-expected regulatory and contract hurdles. The company anticipates a robust second half driven by broader product availability and service growth.
Ada Torres
Ada Torres
13 Feb 2026
Cochlear Limited has announced an ordinary dividend of AUD 2.15 per share for the six months ending December 2025, with payments scheduled for April 2026 and options for currency conversion based on shareholder location.
Ada Torres
Ada Torres
13 Feb 2026
Cochlear Limited posted a modest 1% increase in sales revenue for the half year ending December 2025, while underlying net profit fell 9%, impacted by cloud computing costs and a slower-than-expected Nexa System rollout. The company maintains its dividend and outlines cautious FY26 guidance.
Ada Torres
Ada Torres
13 Feb 2026
Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.
Ada Torres
Ada Torres
12 Feb 2026
Pro Medicus has reported its strongest half-year performance yet, with revenue and profits surging alongside a wave of new multi-million dollar contracts and strategic AI investments. The healthcare IT leader is expanding its global footprint and cloud capabilities, setting the stage for sustained growth.
Ada Torres
Ada Torres
12 Feb 2026